Constructing and contesting markets through the market object

Industrial Marketing Management

Volumn 40, Issue 6, 2011, Pages 899-906

  Finch, John ^a   Geiger, Susi ^b  

^a UNIVERSITY OF STRATHCLYDE   (United Kingdom)

^b UNIVERSITY COLLEGE DUBLIN   (Ireland)

Author keywords

Market development; Market studies; Objectification work; Pharmaceuticals; Product development

Indexed keywords

EID: 80052269350     PISSN: 00198501     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.indmarman.2011.06.034     Document Type: Article

References (49)

1. Ansoff H.I. Strategies for diversification. Harvard Business Review 1957, 35(5):113-124.
2. Ansoff H.I. Corporate strategy 1965, McGraw-Hill, New York.
3. Appadurai A. Introduction: Commodities and the politics of value. The social life of things: Commodities in cultural perspective 1986, 3-63. Cambridge University Press, Cambridge. A. Appadurai (Ed.).
4. Araujo L., Finch J., Kjellberg H. Introduction. Reconnecting marketing to markets 2010, 1-12. Oxford University Press, Oxford. L. Araujo, J. Finch, H. Kjellberg (Eds.).
5. Araujo L., Kjellberg H. Shaping exchanges, performing markets: the study of market-ing practices. The SAGE handbook of marketing theory 2009, 195-218. Sage, London. P. Maclaran, M. Saren, B. Stern, M. Tadajewski (Eds.).
6. Azimont F., Araujo L. Category reviews as market-shaping events. Industrial Marketing Management 2007, 36(7):849-860.
7. Azimont F., Araujo L. The making of a petrol station and the 'on-the-move consumer': Classification devices and the shaping of markets. Industrial Marketing Management 2010, 39(6):1010-1018.
8. Brennan R., Eagle L., Rice D. Medicalization and marketing. Journal of Macromarketing 2010, 30(1):8-22.
9. Brown P.S. Naming and framing: The social construction of diagnosis and illness. Journal of Health and Social Behavior 1995, 36(extra issue):34-52.
10. Çalişkan K., Callon M. Economization, part 2: A research programme for the study of markets. Economy and Society 2010, 39(1):1-32.
11. Callon M. Introduction: The embeddedness of economic markets in economics. The laws of the markets 1998, 1-57. Blackwell, Oxford. M. Callon (Ed.).
12. Callon M. An essay in framing and overflowing: Economic externalities revisited by sociology. The laws of the markets 1998, 244-269. Blackwell, Oxford. M. Callon (Ed.).
13. Callon M., Law J. On qualculation, agency, and otherness. Environment and planning D: Society and space 2004, 23:717-733.
14. Callon M., Muniesa F. Economic markets as calculative collective devices. Organization Studies 2005, 26(8):1229-1250.
15. Caplan P. The debate about PMDD and Sarafem: Suggestions for therapists. Women & Therapy 2004, 27(3/4):55-67.
16. Carolan M.S. The mutability of biotechnology patents: From unwieldy products of nature to independent 'object/s'. Theory, Culture & Society 2010, 27(1):110-129.
17. Conrad P., Leiter V. Medicalization, markets and consumers. Journal of Health and Social Behavior 2004, 45(extra issue):158-176.
18. de Laet M., Mol A. The Zimbabwe bush pump: Mechanics of a fluid technology. Social Studies of Science 2000, 30(2):225-263.
19. Dubois A., Gibbert M. From complexity to transparency: Managing the interplay between theory, method and empirical phenomena in IMM case studies. Industrial Marketing Management 2010, 39(1):129-136.
20. Ellis N., Jack G., Hopkinson G., O'Reilly D. Boundary work and identity construction in market exchanges. Marketing Theory 2010, 10(3):227-236.
21. Engeström Y., Blackler F. On the life of the object. Organization 2005, 12(3):307-330.
22. Figert A.E. Women and the ownership of PMS: The structuring of a psychiatric disorder 1996, Transaction Publishers, Piscataway, NJ.
23. Finch J., Geiger S. Positioning and relating: Market boundaries and the slippery identity of the marketing object. Marketing Theory 2010, 10(3):237-251.
24. Geiger S., Finch J. Industrial sales people as market actors. Industrial Marketing Management 2009, 38:608-617.
25. Greenslit N. Depression and consumption: Psychopharmaceuticals, branding, and new identity practices. Culture, Medicine and Psychiatry 2005, 29(4):477-501.
26. Hagberg J., Kjellberg H. Who performs marketing? Dimensions of agential variation in market practice. Industrial Marketing Management 2010, 39(6):1028-1037.
27. Helgesson C.-F., Kjellberg H. Macro-actors and the sounds of the silenced. Actor network theory and organizing 2005, 175-198. Liber and Copenhagen Business School Press, Malmo and Copenhagen. C. Barbara, H. Tor (Eds.).
28. Karch A.M., Karch F.E. Double dosing. The American Journal of Nursing 2002, 102(10):23.
29. Kjellberg H., Helgesson C.-F. The mode of exchange and shaping of markets: Distributor influence in the Swedish post-war food industry. Industrial Marketing Management 2007, 37(7):861-878.
30. Knaapen L., Weisz G. The biomedical standardization of premenstrual syndrome. Studies in History and Philosophy of Biological and Biomedical Sciences 2008, 39(1):120-134.
31. Latour B. Science in action: How to follow scientists and engineers through society 1987, Open University Press, Milton Keynes.
32. Latour B. Pandora's hope: Essays on the reality of science studies 1999, Harvard University Press, Boston, MA.
33. Law J., Singleton V. Object lessons. Organization 2005, 12(3):331-355.
34. Mattsson L.-G., Johanson J. Discovering market networks. European Journal of Marketing 2006, 40(3/4):259-274.
35. Murray-West R. Galen takes Lilly's reinvented Prozac. Telegraph.co.uk, 10 December 2002 2002, accessed on 10/3/2010.
36. Napoli M. Born-again Prozac: Not worth the extra cost. HealthFacts 2001, 26(7):1.
37. Rinallo D., Golfetto F. Representing markets: The shaping of fashion trends by French and Italian fabric companies. Industrial Marketing Management 2006, 35(7):856-869.
38. Rose N. Neurochemical selves. Society 2003, 46-59. Nov./Dec.,.
39. Shove E., Araujo L. Consumption, materiality and markets. Reconnecting marketing to markets 2010, 13-28. Oxford University Press, Oxford. L. Araujo, J. Finch, H. Kjellberg (Eds.).
40. Slater D. Markets, materiality and the 'New Economy'. Market relations and the competitive process 2002, 95-113. Manchester University Press, Manchester. J.S. Metcalfe, A. Warde (Eds.).
41. Spartos C. Sarafem nation: Renamed Prozac targets huge market: Premenstrual women posted on 05/12/2000, accessed on 09/3/2010. http://www.villagevoice.com.
42. Suchman L. Affiliative objects. Organization 2005, 12(3):379-399.
43. Szegedy-Maszak M. The Career of a celebrity pill. USnew.com, posted 7/29/01 accessed at, on 10/3/2010. http://www.usnews.com.
44. Takayama M., Watanabe C. Myth of market needs and technology seeds as a source of product innovation: An analysis of pharmaceutical new product development in an anti-hypertensive product innovation. Technovation 2002, 22(6):353-362.
45. Takayama M., Watanabe C., Griffy-Brown C. Remaining innovative without sacrificing stability: An analysis of strategies in the Japanese pharmaceutical industry that enable firms to overcome inertia resulting from successful market penetration of new product development. Technovation 2002, 22(12):747-759.
46. Vedantam S. Renamed Prozac fuels women's heath debate 2001, A01. April 29, The Washington Post.
47. Venkatesh A., Peñalosa L., Fuat Firat A. The market as a sign system and the logic of the market. The service-dominant logic of marketing: Dialog, debate and directions 2006, 251-265. M.E. Sharpe, New York. R.F. Lusch, S.L. Vargo (Eds.).
48. Webster F.E. The rediscovery of the marketing concept 1988, 29-39. May-June, Business Horizons.
49. Zwick D., Cayla J. Introduction. Inside marketing: Practices, ideologies, devices 2011, 2-22. Oxford University Press. Z. Detlev, C. Julien (Eds.).